Loading...
XKRX
299660
Market cap23mUSD
May 14, Last price  
3,365.00KRW
Name

Cellid Co Ltd

Chart & Performance

D1W1MN
XKRX:299660 chart
P/E
—
P/S
7.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.36%
Rev. gr., 5y
%
Revenues
4.17b
639,819,81800000909,090,909480,000,00004,165,091,850
Net income
-12.26b
L+5.58%
-1,125,020,075-1,771,574,800-5,408,291,932-11,286,320,640-2,493,555,414-4,125,998,488-13,070,514,497-22,864,575,136-11,611,435,383-12,259,048,230
CFO
-10.32b
L+44.98%
-627,734,785-1,503,756,540-1,371,618,025-1,993,554,889-1,920,789,391-3,763,479,965-8,206,257,337-12,216,037,230-7,115,155,700-10,315,247,180
Dividend
Mar 15, 20220.285 KRW/sh

Profile

Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.
URL
http://www.cellid.co.kr/
IPO date
Feb 20, 2019
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,165,092
 
480,000
-47.20%
Cost of revenue
10,449,494
9,031,224
12,235,646
Unusual Expense (Income)
NOPBT
(6,284,402)
(9,031,224)
(11,755,646)
NOPBT Margin
Operating Taxes
3
5
Tax Rate
NOPAT
(6,284,402)
(9,031,224)
(11,755,646)
Net income
(12,259,048)
5.58%
(11,611,435)
-49.22%
(22,864,575)
74.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
22,675,283
17,199,227
BB yield
-25.40%
-35.72%
Debt
Debt current
53,736
5,507,596
11,918,831
Long-term debt
13,220,286
6,497,558
17,703
Deferred revenue
Other long-term liabilities
3,658,430
3,451,035
2,870,440
Net debt
4,178,740
(5,688,406)
(10,774,955)
Cash flow
Cash from operating activities
(10,315,247)
(7,115,156)
(12,216,037)
CAPEX
(5,908,403)
(11,411,185)
(1,202,950)
Cash from investing activities
(15,066,210)
(751,879)
14,001,708
Cash from financing activities
21,025,002
12,993,427
1,263,457
FCF
(10,666,908)
(28,713,930)
(10,162,861)
Balance
Cash
9,069,319
15,413,210
18,644,869
Long term investments
25,963
2,280,350
4,066,619
Excess cash
8,887,028
17,693,560
22,687,488
Stockholders' equity
(54,470,165)
(45,894,501)
(26,818,284)
Invested Capital
122,503,772
101,835,624
64,055,295
ROIC
ROCE
EV
Common stock shares outstanding
17,640
10,771
10,678
Price
5,060.00
13.20%
4,470.00
-61.96%
11,750.00
-76.07%
Market cap
89,259,377
85.40%
48,145,208
-61.63%
125,468,920
-76.02%
EV
93,438,117
42,456,802
114,693,966
EBITDA
(3,550,895)
(6,367,642)
(9,155,572)
EV/EBITDA
Interest
471,957
1,264,465
1,628,293
Interest/NOPBT